Pipeline

Advancing Novel T Cell Engaging Immunotherapies

Harpoon is a clinical-stage immuno-oncology company building a pipeline of wholly-owned immunotherapies harnessing the tumor-killing power of T cells for patients with difficult-to-treat tumors.

TriTAC

PSMA
Prostate Cancer
    
MSLN
Ovarian Cancer & Other Solid Tumors
    
BCMA
Multiple Myeloma
    
DLL3
Small Cell Lung Cancer
    

ABBV-189

Survivin
Multiple tumors
    

Discovery

Various
    

ProTriTAC

EpCAM
GI Cancers
    

Discovery

Various
    
Product Candidate
Target/Indication

For a description of our ongoing clinical studies, please visit clinicaltrials.gov.